SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the efficacy, safety and tolerability of SHR6390 in
combination with nab-paclitaxel and gemcitabine in first-line treatment of subjects with
advanced/metastatic pancreatic cancer.